medigraphic.com

2020, Número 2

<< Anterior Siguiente >>

Rev Mex Anest 2020; 43 (2)


Coronavirus-2019. Consideraciones Generales

Sánchez-Zúñiga MJ, Carrillo-Esper R

Idioma: Español
Referencias bibliográficas: 20
Paginas: 83-91
Archivo PDF: 451.51 Kb.


RESUMEN

De acuerdo a lo publicado por la OMS (Organización Mundial de la Salud) un primer caso de infección respiratoria aguda, de origen desconocido, apareció en la provincia de Hubei, China, en la ciudad de Wuhan (diciembre de 2019). Después de haberse descartado otros agentes etiológicos se logró el aislamiento de un nuevo coronavirus (07-01-2020), al que se denominó nuevo coronavirus (nCOV, COVID-19), en la actualidad nombrado como SARS-CoV-2. Los coronavirus son patógenos importantes, pueden infectar el sistema respiratorio, gastrointestinal, hepático, nervioso, tanto de humanos como de aves, ganado, murciélagos, ratones y otros animales salvajes. Desde los brotes de SARS (síndrome agudo respiratorio severo) en 2002 y MERS (síndrome respiratorio de Medio Oriente) en 2012, se ha logrado demostrar la transmisión de estos virus entre humanos y animales.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Health Organization Press Conference. The World Health Organization (WHO) Has Officially Named the Disease Caused by the Novel Coronavirus as COVID-19. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.

  2. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020;12. doi: 10.3390/v12040372.

  3. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27:325-328.

  4. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020;395:565-574.

  5. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)-China, 2020. China CDC Weekly. (Accessed February 20, 2020). Available in: http://weekly. chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51.

  6. Chen L, Liu W, Zhang Q, Xu K, Ye G, Wu W, et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg Microbes Infect. 2020;9:313-319. doi: 10.1080/22221751.2020.1725399.

  7. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181-192. doi: 10.1038/s41579-018-0118-9.

  8. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-1242.

  9. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63:364-374.

  10. Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci (Lond). 2020;134:543-545.

  11. Bavishi C, Maddox TM, Messerli FH. Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers. JAMA Cardiol. 2020. doi: 10.1001/jamacardio.2020.1282. [Epub ahead of print].

  12. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-454.

  13. Lineamiento estandarizado para la vigilancia epidemiológica y por laboratorio de COVID-19. Disponible en: https://www.gob.mx/salud/documentos/nuevo-coronavirus.

  14. Wujtewicz MA, Dylczyk-Sommer A, Aszkiełowicz A, Zdanowski S, Piwowarczyk S, Owczuk. COVID-19-what should anaethesiologists and intensivists know about it? Anaesthesiol Intensive Ther. 2020;52:1-18.

  15. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020;28:1-34. doi: 10.1007/s00134-020-06022-5. Epub ahead of print. PMID: 32222812; PMCID: PMC7101866.

  16. Arabi YM, Murthy S, Webb S. Correction to: COVID-19: a novel coronavirus and a novel challenge for critical care [published online ahead of print, 2020 Mar 18]. Intensive Care Med. 2020;46:1-2. doi: 10.1007/s00134-020-06009-2.

  17. Bouadma L, Lescure FK, Lucet JC, Yazdanpanah Y, Timsit JF. Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists Intensive Care Med. 2020;46:579-582.

  18. McCloskey B, Heymann DL. SARS to novel coronavirus: old lessons and new lessons. Epidemiol Infect. 2020; 148: e22. doi: 10.1017/S0950268820000254.

  19. Peng QY, Wang XT, Zhang LN. Chinese Critical Care Ultrasound Study Group (CCUSG). Findings of lung ultrasonography of novel corona virus pneumonia during the 2019–2020 epidemic. Intensive Care Med https://doi.org/10.1007/s00134-020-05996-6.

  20. Zhang W. Imaging changes in severe COVID-19 pneumonia. Intensive Care Med. 2020;46:583-585. https://doi.org/10.1007/s00134-020-05976-w.




2020     |     www.medigraphic.com